Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy.
Immunotherapy
Macrophages
Tumor Escape
Tumor Microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
accepted:
21
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
16
3
2023
Statut:
ppublish
Résumé
Primary and secondary resistance is a major hurdle in cancer immunotherapy. Therefore, a better understanding of the underlying mechanisms involved in immunotherapy resistance is of pivotal importance to improve therapy outcome. Here, two mouse models with resistance against therapeutic vaccine-induced tumor regression were studied. Exploration of the tumor microenvironment by high dimensional flow cytometry in combination with therapeutic Comparison of the tumor immune infiltrate during early and late regression revealed a change from tumor-rejecting toward tumor-promoting macrophages. In concert, a rapid exhaustion of tumor-infiltrating T cells was observed. Perturbation studies identified a small but discernible CD163 In this study, a small population of CD163
Sections du résumé
BACKGROUND
Primary and secondary resistance is a major hurdle in cancer immunotherapy. Therefore, a better understanding of the underlying mechanisms involved in immunotherapy resistance is of pivotal importance to improve therapy outcome.
METHOD
Here, two mouse models with resistance against therapeutic vaccine-induced tumor regression were studied. Exploration of the tumor microenvironment by high dimensional flow cytometry in combination with therapeutic
RESULTS
Comparison of the tumor immune infiltrate during early and late regression revealed a change from tumor-rejecting toward tumor-promoting macrophages. In concert, a rapid exhaustion of tumor-infiltrating T cells was observed. Perturbation studies identified a small but discernible CD163
CONCLUSIONS
In this study, a small population of CD163
Identifiants
pubmed: 36914207
pii: jitc-2022-006433
doi: 10.1136/jitc-2022-006433
pmc: PMC10016286
pii:
doi:
Substances chimiques
CD163 antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Science. 2021 Jun 11;372(6547):
pubmed: 34112666
Immunity. 2017 Aug 15;47(2):323-338.e6
pubmed: 28813661
Nat Med. 2022 Feb;28(2):333-344
pubmed: 35027753
PLoS One. 2012;7(12):e50946
pubmed: 23284651
Oncotarget. 2015 Sep 29;6(29):27832-46
pubmed: 26337837
Int J Biol Sci. 2019 Mar 10;15(5):984-998
pubmed: 31182919
Front Physiol. 2014 Mar 05;5:75
pubmed: 24634660
Nat Immunol. 2016 Feb;17(2):159-68
pubmed: 26642357
Urol Oncol. 2014 May;32(4):449-57
pubmed: 24252833
Int J Cancer. 2007 Feb 1;120(3):500-5
pubmed: 17066448
Cancers (Basel). 2021 May 08;13(9):
pubmed: 34066839
Cell. 2020 Oct 15;183(2):377-394.e21
pubmed: 32976798
PLoS One. 2015 Sep 03;10(9):e0136654
pubmed: 26335330
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32771994
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32873723
PLoS One. 2012;7(5):e36814
pubmed: 22590615
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Cancers (Basel). 2021 Nov 12;13(22):
pubmed: 34830831
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
Front Cardiovasc Med. 2019 Jul 31;6:101
pubmed: 31417911
Cancer Res. 2015 Sep 1;75(17):3479-91
pubmed: 26269531
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32369450
Front Immunol. 2021 Mar 31;12:658315
pubmed: 33868304
Cells. 2021 Apr 20;10(4):
pubmed: 33924237
Front Physiol. 2018 May 01;9:419
pubmed: 29765329
Cancer Immunol Res. 2014 Feb;2(2):121-6
pubmed: 24778275
Immunol Today. 1994 Oct;15(10):490-5
pubmed: 7945775
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34
pubmed: 15701862
Nat Commun. 2015 May 13;6:7114
pubmed: 25968334
PLoS One. 2015 Dec 23;10(12):e0145342
pubmed: 26699615
Nat Rev Cancer. 2019 Oct;19(10):568-586
pubmed: 31462760
Nat Med. 2019 Apr;25(4):612-619
pubmed: 30833751
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
pubmed: 20160101
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32690771
J Control Release. 2012 May 30;160(1):72-80
pubmed: 22306335
Annu Rev Pharmacol Toxicol. 1997;37:517-54
pubmed: 9131263
PLoS One. 2014 Aug 11;9(8):e104230
pubmed: 25110953
Immunobiology. 2020 Jan;225(1):151862
pubmed: 31711674
Nat Immunol. 2004 Feb;5(2):141-9
pubmed: 14704792
Nat Commun. 2019 Nov 28;10(1):5415
pubmed: 31780669
Semin Immunol. 2021 Apr;54:101514
pubmed: 34776301
Oncoimmunology. 2013 Dec 1;2(12):e26968
pubmed: 24498562
J Exp Med. 2018 Oct 1;215(10):2536-2553
pubmed: 30201786
PLoS One. 2011;6(7):e21800
pubmed: 21789182
J Immunother Cancer. 2022 May;10(5):
pubmed: 35618288
Curr Protoc Pharmacol. 2016 Jun 01;73:14.39.1-14.39.20
pubmed: 27248578
Front Immunol. 2019 Jul 26;10:1765
pubmed: 31402920
Cancer Immunol Res. 2015 Feb;3(2):149-60
pubmed: 25387892
Cancer Cell. 2021 Jul 12;39(7):973-988.e9
pubmed: 34115989
J Clin Invest. 2020 Apr 1;130(4):2081-2096
pubmed: 31945018
J Exp Med. 2019 Oct 7;216(10):2394-2411
pubmed: 31375534
JAMA Oncol. 2019 Jan 1;5(1):67-73
pubmed: 30267032
Cells. 2019 Jan 23;8(2):
pubmed: 30678058
Blood. 2015 Sep 10;126(11):1357-66
pubmed: 26232173
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Cancer Lett. 2019 Aug 10;457:168-179
pubmed: 31078738
Front Cell Dev Biol. 2020 Feb 11;8:17
pubmed: 32117960
Cell. 2018 Dec 13;175(7):1744-1755.e15
pubmed: 30503208
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31951251
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Blood. 2010 Aug 5;116(5):829-40
pubmed: 20404134
Science. 2019 Mar 15;363(6432):
pubmed: 30872492
Cancers (Basel). 2021 Sep 30;13(19):
pubmed: 34638400
Nature. 2021 Jul;595(7868):578-584
pubmed: 34135508
PLoS One. 2013 Nov 15;8(11):e80908
pubmed: 24260507
Cancers (Basel). 2020 Apr 10;12(4):
pubmed: 32290124
J Exp Med. 2010 Aug 2;207(8):1791-804
pubmed: 20660615
Cancer Immunol Res. 2015 Sep;3(9):1042-51
pubmed: 25888578
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
Clin Cancer Res. 2018 Apr 1;24(7):1617-1628
pubmed: 29339440
Cancer Immunol Immunother. 2014 Mar;63(3):247-57
pubmed: 24357148
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
J Exp Med. 1997 Nov 3;186(9):1407-18
pubmed: 9348298
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Cancer Res. 1996 Jan 1;56(1):21-6
pubmed: 8548765
J Immunol. 2002 Jun 1;168(11):5538-50
pubmed: 12023349